Actuate Therapeutics (NASDAQ:ACTU – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued on Tuesday, MarketBeat.com reports.
A number of other brokerages have also recently issued reports on ACTU. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen downgraded shares of Actuate Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Finally, Rodman & Renshaw initiated coverage on shares of Actuate Therapeutics in a report on Thursday, July 30th. They set a “buy” rating and a $6.00 target price for the company. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $13.67.
Read Our Latest Stock Report on ACTU
Actuate Therapeutics Stock Down 2.0%
Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01. Equities analysts anticipate that Actuate Therapeutics will post -0.86 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ABS Direct Equity Fund LLC purchased a new stake in Actuate Therapeutics in the fourth quarter worth approximately $40,000. Deutsche Bank AG raised its stake in Actuate Therapeutics by 640.0% during the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock valued at $57,000 after buying an additional 8,051 shares during the last quarter. Barclays PLC lifted its holdings in shares of Actuate Therapeutics by 68.6% during the 4th quarter. Barclays PLC now owns 14,946 shares of the company’s stock valued at $91,000 after buying an additional 6,081 shares during the period. Bank of America Corp DE boosted its stake in shares of Actuate Therapeutics by 61,068.0% in the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company’s stock worth $93,000 after buying an additional 15,267 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Actuate Therapeutics in the 4th quarter worth $102,000.
About Actuate Therapeutics
Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.
The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.
See Also
- Five stocks we like better than Actuate Therapeutics
- 3 Infrastructure Stocks Built Around the Backbone of the Economy
- Moonshot to Money: Intuitive Machines Lands $600M Defense Win
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
Receive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
